10-Q: Co-Diagnostics Reports Q1 2025 Results: Revenue Declines Amidst Development of Point-of-Care Platform

Sentiment:

Quarterly Report 8 May 2025 4:10 PM

Co-Diagnostics, Inc. reports a decrease in revenue for Q1 2025 compared to Q1 2024, while continuing to focus on the development and regulatory approval of its Co-Dx PCR platform.

Delay expectedThe company withdrew its initial FDA 510(k) application for its Co-Dx PCR platform and plans to resubmit an enhanced version, indicating a delay in the platform's commercialization.

Capital raiseThe company has entered into an Amended and Restated Equity Distribution Agreement (the ATM Agreement) with Piper Sandler & Co. (Piper Sandler) and Clear Street, LLC (Clear Street), pursuant to which it may offer and sell shares of its common stock having an aggregate offering price of up to $17,111,650 from time to time through Piper Sandler and Clear Street acting as agents.As of March 31, 2025, the Company has sold 833,806 shares of common stock under the ATM Agreement resulting in net proceeds to the Company of $ 0.6 million.As of March 31, 2025, the Company has up to $ 16.5 million remaining in aggregate gross proceeds that can be issued through the ATM Agreement.

Worse than expectedThe company's revenue decreased significantly compared to the same period last year, indicating a decline in business performance.

Summary

Co-Diagnostics, Inc. reported its financial results for the first quarter of 2025.
Total revenue decreased to $50,277 from $467,854 in the same period last year, due to lower product and grant revenues.
The net loss for the quarter was $7.5 million, an improvement compared to the $9.3 million loss in Q1 2024.
Operating expenses decreased to $8.6 million from $10.5 million year-over-year, driven by lower stock-based compensation and development expenses.
The company had cash and cash equivalents of $1.9 million and marketable investment securities of $19.6 million as of March 31, 2025.
Co-Diagnostics is focusing on the development and regulatory approval of its Co-Dx PCR platform for point-of-care and at-home use.
The company withdrew its initial FDA 510(k) application for the Co-Dx PCR Pro instrument and COVID-19 test to address shelf-life stability concerns and plans to resubmit an enhanced version.
The company is funding its operations through equity financing, including an at-the-market (ATM) agreement, and is seeking additional grant funding and operational efficiencies.
There is substantial doubt about the company's ability to continue as a going concern for the next 12 months without additional capital.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to the significant revenue decline, the withdrawal of the FDA application, and the going concern warning. However, the company is taking steps to address these challenges and is focused on developing its Co-Dx PCR platform.

Positives

The net loss decreased from $9.3 million to $7.5 million compared to the same quarter last year.
Operating expenses decreased due to lower stock-based compensation and development expenses.
The company is actively pursuing regulatory approval for its Co-Dx PCR platform.
The company has access to additional capital through its ATM agreement.

Negatives

Revenue decreased significantly from $467,854 to $50,277 compared to the same quarter last year.
The company withdrew its initial FDA 510(k) application for its Co-Dx PCR platform.
There is substantial doubt about the company's ability to continue as a going concern.

Risks

The company's ability to continue as a going concern is dependent on obtaining additional financing and generating profitable operations.
The company's ability to obtain additional financing is subject to market and economic conditions and investor sentiment.
There is no assurance that the company will be able to raise a sufficient amount of additional capital to fund operations.
The Co-Dx PCR platform may not receive the necessary regulatory approvals for commercialization.
The company is a defendant in one class action claim and four derivative actions claiming that the Company promulgated false and misleading press releases to increase the price of our stock to improperly benefit the officers and directors of the Company.
The company is also a party to three civil actions, two in the US and the other in the United Kingdom. Each of the civil actions is based on breach of contract claims against the Company.

Future Outlook

The company is focused on obtaining regulatory approval for its Co-Dx PCR platform and plans to resubmit an enhanced version of its COVID-19 test for 510(k) OTC clearance. The company anticipates continuing to generate operating losses and use cash in operations in the near term and expects to fund operations through equity financing, grant funding, and operational efficiencies.

Management Comments

The company is focused on the development and regulatory approval of its Co-Dx PCR platform for point-of-care and at-home use.
The decision to withdraw the submission was based on discussions with the FDA regarding the ability to detect a potential deterioration of one component of the test, related to shelf-life stability.
The Company plans to submit the next iteration of the Co-Dx PCR COVID-19 test for 510(k) OTC clearance, following the collection of clinical evaluation data to support the new tests performance.

Industry Context

The molecular diagnostics industry is competitive and rapidly evolving. Co-Diagnostics is positioning itself as a low-cost provider of molecular diagnostics and screening services through its proprietary technology. The company's focus on point-of-care and at-home testing aligns with the growing trend of decentralized diagnostics.

Comparison to Industry Standards

It is difficult to compare Co-Diagnostics directly to industry standards without more specific information on its competitors and their performance.
Companies like QuidelOrtho and Roche are major players in the diagnostics market, but their product portfolios and target markets differ from Co-Diagnostics.
The company's revenue decline suggests it is struggling to compete in the current market environment, particularly with the reduced demand for COVID-19 testing.
The success of the Co-Dx PCR platform will be critical to the company's future performance.

Legal Proceedings

The Company is a defendant in one class action claim and four derivative actions claiming that the Company promulgated false and misleading press releases to increase the price of our stock to improperly benefit the officers and directors of the Company.
The Company is also a party to three civil actions, two in the US and the other in the United Kingdom.
Each of the civil actions is based on breach of contract claims against the Company.

Related Party Transactions

The Company has a services agreement with CoSara Diagnostics Pvt Ltd (CoSara), our joint venture for manufacturing in India, under which CoSara provides certain research and development consulting and support services.
The Company recognized $ 0.2 million and $ 0.1 million of expense related to this agreement during the three months ended March 31, 2025 and 2024, respectively.

Stakeholder Impact

Shareholders face the risk of dilution from potential equity financing.
Employees face uncertainty due to the company's financial challenges.
Customers may experience delays in the availability of the Co-Dx PCR platform.
Suppliers and creditors face increased risk due to the company's going concern warning.

Next Steps

Resubmit an enhanced version of the COVID-19 test for 510(k) OTC clearance.
Collect clinical evaluation data to support the new test's performance.
Continue to develop and commercialize the Co-Dx PCR platform.
Seek additional equity and/or debt financing.
Generate profitable operations.

Key Dates

Date	Description
2022-03	The Companys Board of Directors authorized a share repurchase program that would allow the Company to repurchase up to $ 30.0 million of CODX common stock.
2022-08-31	The shareholders approved an increase in the number of awards available for issuance under the Incentive Plan to an aggregate of 12,000,000 shares of common stock.
2024-06	The company completed its first U.S. Food and Drug Administration (FDA) application for 510(k) clearance for the Co-Dx PCR Pro instrument, the Co-Dx PCR COVID-19 Test, and the Co-Dx PCR mobile app for over-the-counter (OTC) use.
2024-10-18	Prospectus supplement date for the Amended and Restated Equity Distribution Agreement (the ATM Agreement) with Piper Sandler & Co. (Piper Sandler) and Clear Street, LLC (Clear Street).
2025-03-27	Filing date of the Company's Annual Report on Form 10-K for the year ended December 31, 2024.
2025-03-31	End of the quarterly period for this report.
2025-05-05	Date as of which there were 33,712,530 shares of common stock outstanding.
2025-05-08	Date of report.

Keywords

Co-Diagnostics, PCR, diagnostics, revenue, FDA, COVID-19, financial results, molecular diagnostics, Co-Dx PCR platform, ATM agreement

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.